FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,
Farapulse, Inc. · Decision date Oct 2, 2026
What did the FDA decide?
FDA records P230030/S025 as a supplement to PMA P230030, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 2, 2026.
FDA approval order statement
an additional supplier location site
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 2, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P230030/S025
- Regulatory pathway
- PMA supplement
- Applicant
- Farapulse, Inc.
- Product code
- QZI
- Decision code
- OK30
- Decision date
- Oct 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.
- Applicant
- Farapulse, Inc.
- Product code
- QZI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230030. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230030 · Original PMA
FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,
P230030/S024 · Related supplement
FARASTAR Pulsed Field Ablation (PFA) Generator; FARASTAR Mapping System Module (MSM); FARASTAR Recording System Modul
P230030/S025 received
Application receipt date recorded by FDA.
P230030/S025 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P230030. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230030
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Farapulse, Inc. | PMA approval | Jan 30, 2024 | FDA | |
| Farapulse, Inc. | PMA supplement | Sep 4, 2026 | FDA |
Explore the linked device profile
Other records with product code QZI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Varipulse Bi-Directional CatheterP240006/S018 | Biosense Webster, Inc. | PMA supplement | Nov 3, 2026 | FDA |
Globe Catheter and Globe Pulsed Field SystemP240044/S007 | Kardium, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Globe Pulsed Field System; Globe CatheterP240044/S008 | Kardium, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Volt PFA SystemP250022/S002 | ABBOTT MEDICAL | PMA supplement | Oct 15, 2026 | FDA |
Affera Sphere-9 Mapping and Ablation CatheterP240013/S032 | Medtronic, Inc. | PMA supplement | Oct 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Farapulse, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3715 Haven Ave., Suite 110, Menlo Park, CA, 94025
Sources and methodology
- Original FDA record: P230030/S025
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

